Biblioteca Digital

8 resultados para 186-1151

em QUB Research Portal - Research Directory and Institutional Repository for Queen's University Belfast

High activity Rhenium-186 HEDP with autologous peripheral blood peripheral blood stem cell rescue- a phase I study in progressive hormone refractory prostate cancer metastatic to bone

Relevância:

20.00% 20.00%

Publicador:

A model-based method for the prediction of whole body absorbed dose and bone marrow toxicity for ¹⁸⁶Re-HEDP treatment of skeletal metastases from prostate cancer

Relevância:

20.00% 20.00%

Publicador:

Tumor dosimetry on SPECT Re-186-HEDP scans: Variations in the results from the reconstruction methods used

Relevância:

20.00% 20.00%

Publicador:

High activity rhenium-186 hydroxyethylidene diphosphonate (HEDP) with autologous peripheral blood stem cell (PBSC) transplant: A novel treatment strategy in hormone refractory prostate cancer metastatic to bone.

Relevância:

20.00% 20.00%

Publicador:

Comparison of PSA measurements and scintigraphy in patients with skeletal metastases from carcinoma of the prostate treated with high activities of Re 186 HEDP.

Relevância:

20.00% 20.00%

Publicador:

Prediction of response of skeletal metastases from cancer of the prostate to high activity Re-186 HEDP therapy.

Relevância:

20.00% 20.00%

Publicador:

Autologous peripheral blood stem cell rescue permits administration of high activities of rhenium-186 HEDP in progressive hormone refractory prostate cancer metastatic to bone

Relevância:

20.00% 20.00%

Publicador:

A phase I study of combined docetaxel and repeated high activity Re-186-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial)

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Purpose Bone-seeking radiopharmaceuticals have palliative benefit in castration-resistant prostate cancer (CRPC) metastatic to bone. Recent studies have shown improvement of survival and quality of life when radiopharmaceuticals were given repeatedly or in combination with chemotherapy. We designed a phase I study combining docetaxel and Re-186-labelled hydroxyethylidene diphosphonate (HEDP) in men with CRPC and bone metastases to evaluate toxicity.